Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Pediatrix Medical Group Inc (NYSE: MD) closed the day trading at $13.5 down -0.44% from the previous closing price of $13.56. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 0.62 million shares were traded. MD stock price reached its highest trading level at $13.68 during the session, while it also had its lowest trading level at $13.21.
Ratios:
For a better understanding of MD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.97. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.79.
On September 26, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $8 to $14.
Deutsche Bank Upgraded its Sell to Hold on June 07, 2024, while the target price for the stock was maintained at $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 ’25 when Swift James D bought 18,530 shares for $16.63 per share.
ORDAN MARK S sold 27,600 shares of MD for $423,660 on Nov 13 ’24. The Director now owns 138,683 shares after completing the transaction at $15.35 per share. On Nov 13 ’24, another insider, ORDAN MARK S, who serves as the Director of the company, bought 27,600 shares for $15.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MD now has a Market Capitalization of 1159726848 and an Enterprise Value of 1644545920. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.59 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 0.832 whereas that against EBITDA is 7.3.
Stock Price History:
The Beta on a monthly basis for MD is 1.22, which has changed by 0.82432437 over the last 52 weeks, in comparison to a change of 0.11844492 over the same period for the S&P500. Over the past 52 weeks, MD has reached a high of $17.67, while it has fallen to a 52-week low of $6.69. The 50-Day Moving Average of the stock is -2.94%, while the 200-Day Moving Average is calculated to be -2.11%.
Shares Statistics:
Over the past 3-months, MD traded about 845.75K shares per day on average, while over the past 10 days, MD traded about 613250 shares per day. A total of 85.81M shares are outstanding, with a floating share count of 84.40M. Insiders hold about 1.76% of the company’s shares, while institutions hold 88.71% stake in the company. Shares short for MD as of 1749772800 were 2178973 with a Short Ratio of 2.58, compared to 1747267200 on 1393134. Therefore, it implies a Short% of Shares Outstanding of 2178973 and a Short% of Float of 3.56.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Pediatrix Medical Group Inc (MD) is currently in the spotlight, with 8.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.44, with high estimates of $0.48 and low estimates of $0.41.
Analysts are recommending an EPS of between $1.73 and $1.6 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $1.72, with 8.0 analysts recommending between $1.84 and $1.6.
Revenue Estimates
8 analysts predict $464.37M in revenue for the current quarter. It ranges from a high estimate of $490.01M to a low estimate of $446.81M. As of the current estimate, Pediatrix Medical Group Inc’s year-ago sales were $504.3MFor the next quarter, 8 analysts are estimating revenue of $472.84M. There is a high estimate of $506.92M for the next quarter, whereas the lowest estimate is $452.89M.
A total of 8 analysts have provided revenue estimates for MD’s current fiscal year. The highest revenue estimate was $1.96B, while the lowest revenue estimate was $1.85B, resulting in an average revenue estimate of $1.87B. In the same quarter a year ago, actual revenue was $2.01BBased on 8 analysts’ estimates, the company’s revenue will be $1.93B in the next fiscal year. The high estimate is $2.02B and the low estimate is $1.85B.
